Informational Alert

Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

High Priority Alert

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines .

Current Research Studies

Larotrectinib to enhance RAI avidity in patients with differentiated thyroid cancer harboring NTRK fusions

SC-4021, Larotrectinib pre-RAI in patients with NTRK fusion thyroid cancer (LANTERN)

  • Condition(s): Thyroid
  • Phase: II
  • Clinicaltrials.gov ID: NCT05783323

What is the goal of the study?

Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies. This is an open label, non-randomized study to evaluate the efficacy and safety of the combination of larotrectinib followed by 131I therapy for patients with NTRK fusion differentiated thyroid cancer. The primary Phase II objective will be to evaluate the pulmonary structural response rate at 18 months to the combination of larotrectinib given for 6-months followed by 131I therapy.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: